[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"orthopedics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:orthopedics":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,91,117,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644540","phase-3-tranexamic-acid-to-reduce-blood-loss-after-varus-derotation-osteotomy-100644540",false,"NCT07672158","Tranexamic Acid to Reduce Blood Loss After Varus Derotation Osteotomy","Postoperative Continuous Intravenous Tranexamic Acid Infusion to Reduce Blood Loss in Non-Ambulatory Children With Cerebral Palsy Following Bilateral Bony Hip Reconstructive Surgery: A Phase III Parallel-Group Randomised Placebo-Controlled Trial","TABLO","Inclusion Criteria:\n\n* Children (aged 4 to 16 years)\n* Diagnosis of cerebral palsy (CP). CP is an umbrella term under which many specific diagnoses are captured, and the clinical team at the study institution operates a comprehensive referral network to ensure patients with any relevant diagnoses are included.\n* Gross Motor Function Classification System (GMFCS) levels IV and V, with substantial hip displacement (\\>40% migration percentage per Australian Hip Surveillance Guidelines (Wynter M, Gibson N, Kentish M, Love S, Thomason P, Willoughby K, et al. Australian hip surveillance guidelines for children with cerebral palsy 2014. Australian Academy of Cerebral Palsy and Developmental Medicine. 2014.)), who are on the waitlist for bilateral proximal femoral varus derotational osteotomy (VDRO) +\u002F- unilateral or bilateral pelvic osteotomy.\n\nExclusion Criteria:\n\n* Haematological disorder (defined as an active genetic or acquired bleeding disorder)\n* Known hypersensitivity to tranexamic acid (TXA)\n* Children with promyelocytic leukaemia being treated with oral tretinoin will be excluded from the trial because combination with TXA has resulted in fatal thrombotic complications\n* Known coagulation defect\n* Known renal disorder (moderate to severe as per study institution guidelines)","ALL","4 Years","16 Years",{"count":21,"type":22},52,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","TABLO (Tranexamic Acid to reduce Blood Loss after varus derotation Osteotomy) is a clinical trial of postoperative tranexamic acid vs placebo in non-ambulatory children with cerebral palsy (CP) undergoing reconstructive hip surgery.\n\nImproving surgical outcomes is a high priority in this patient population given the high risk of bleeding and the diminished capacity for these children to withstand substantial blood loss. Preliminary data from the study institution indicates that approximately one third of these patients receive transfusion of blood products in the postoperative period. There is growing evidence that hidden blood loss occurring in the postoperative period is substantial and can potentially be attenuated with the administration of Tranexamic Acid (TXA). However, trials on postoperative TXA have been carried out exclusively in adult surgical populations.",[28,29,30,31,32,33],"Cerebral Palsy","Hip Surgery Corrective","Tranexamic Acid Use","Blood Loss, Surgical","Paediatrics","Orthopedics",[28,35,36,37,38],"Hip surgery","Tranexamic Acid","Blood Loss","Orthopaedics","NOT_YET_RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-26","ACTUAL",{"date":45,"type":22},"2026-07",{"date":47,"type":22},"2029-04",{"name":49,"class":50},"Murdoch Childrens Research Institute","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100641416","patient-ai-trust-dynamics-before-and-after-orthopedic-consultation-ortho-op-gpt-100641416","NCT07631585","Patient AI Trust Dynamics Before and After Orthopedic Consultation (ORTHO-OP-GPT)","Longitudinal Pre-Post Patient AI Trust Dynamics in Orthopedic Outpatients: A Mixed-Methods Observational Study With Matched Physician-Patient Dyads","ORTHO-OP-GPT","Inclusion Criteria:\n\n* Age 18 years or older\n* Presenting to an orthopedic outpatient clinic for any consultation\n* Able to read and respond to a Turkish-language questionnaire\n* Provides informed consent\n\nExclusion Criteria:\n\n* Inability to complete a self-report questionnaire (e.g., severe cognitive impairment, language barrier)\n* Re-presentation within the same recruitment window (each patient is enrolled only once)\n* Refusal of consent for either T0 or T1","18 Years",{"count":62,"type":22},180,"OBSERVATIONAL","Patients increasingly consult artificial intelligence (AI) chatbots such as ChatGPT for health information before clinical visits, yet the impact of an actual orthopedic consultation on patient trust in AI-derived information remains unknown. This prospective longitudinal observational study quantifies how a single orthopedic outpatient consultation modifies patient trust in AI chatbots, the concordance between AI-derived and physician-delivered information, and patient anxiety, using a paired pre-post survey design supplemented by a matched physician-side assessment. Adult patients (18 years and older) presenting to two orthopedic outpatient clinics in Cyprus complete a brief pre-consultation questionnaire (T0) capturing demographics, AI use patterns, prior AI consultation regarding the current complaint, baseline trust, expectations, and anxiety. Immediately after their consultation they complete a second questionnaire (T1) assessing concordance with physician advice, trust change, consultation facilitation, post-consultation anxiety, and future intention. The consulting physician completes a brief 30-second post-visit form capturing whether AI was discussed, the medical accuracy of AI-derived information conveyed by the patient, and the effect of the AI discussion on consultation duration. The primary outcomes are the paired within-patient change in AI trust between T0 and T1 and physician-patient concordance on AI versus physician advice. Target enrollment is 180 to obtain 150 paired completed assessments.",[66,67,68,33],"Patient Health Information Seeking Behavior","Trust","Health Literacy",[70,71,72,73,74,75,76,77,78,79],"ChatGPT","large language model","artificial intelligence chatbot","patient education","health information seeking","trust","physician-patient communication","orthopedics","cross-sectional","pre-post","RECRUITING","2026-06-14",{"date":83,"type":43},"2026-06-17",{"date":85,"type":22},"2026-06",{"date":87,"type":22},"2027-01",{"name":89,"class":50},"Utku Gürhan",2,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":116},"100373039","hand--wrist-pyrocarbon-implants-outcomes-clinical-study-100373039","NCT04137237","Hand & Wrist Pyrocarbon Implants Outcomes Clinical Study","HaWPYC","Inclusion Criteria:\n\n* 18 years or older at the time he\u002Fshe receives the information and signs the informed consent (when applicable as per local regulatory requirements),\n* Informed on the study and willing to sign an informed consent form approved by Institutional Review Board or Ethics Committee,\n* Willing and able to comply with the requirements of the study protocol,\n* For prospective inclusion: considered for treatment with one of PyC Hand\u002FWrist study implants (primary or revision surgery),\n* For \"ambispective\" inclusion: must have undergone a Hand or Wrist arthroplasty with a PyC Hand\u002FWrist study implant before the date of first site initiation visit,\n\n  * Follow-up visits (at least the last two) must be prospective,\n  * Patient must have complete information available for each completed visit\n\nExclusion Criteria:\n\n* Patient pertaining to one of the categories referred to as \"vulnerable population\" in the French Law (articles L. 1121-5 to L. 1121-8 of the French Public Health Code), or as \"particularly vulnerable persons\" in the Swiss Federal Law (Chapter 3, Sections 1 to 4 of CC 810.30 Federal Act on Research involving Human Beings - Human Research Act, HRA),\n* Patient unable to comply with the study procedures based on the judgment of the investigator (e.g. cannot comprehend study questions, inability to keep scheduled assessment times),\n* Any medical condition that could impact on the study outcomes functional signification at the investigator's discretion (e.g., neuropathy, allergy…)",{"count":99,"type":22},417,"HaWPYC is an international Post-Market Clinical Follow-up (PMCF) to collect post-market safety and performance data on commercially available Pyrocarbon (PyC) hand and wrist implants used in this study. Data may be used for Post-Market Surveillance, and regulatory requirements.",[33],[103,104,105],"Hand","Wrist","Surgery","2025-09-09",{"date":108,"type":43},"2025-09-16",{"date":110,"type":43},"2019-11-14",{"date":112,"type":22},"2033-01",{"name":114,"class":115},"Stryker Trauma and Extremities","INDUSTRY",4,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":51},"100414537","trabecular-metal-economic-and-clinical-knee-trial-100414537","NCT04677907","TRabecular Metal Economic and Clinical Knee Trial","Health Economic and Clinical Comparison of Trabecular Metal Uncemented and Cemented Modular Total Knee Replacements - A Double Blinded Randomised Controlled Trial","TRECK","Inclusion Criteria:\n\n* Male or female subjects may be recruited to the evaluation.\n* Age - there are no restrictions relating to age of the patient.\n* Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.\n* Subjects who in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigation procedures and are willing to return to the hospital for all the required post-operative follow-ups.\n* Subjects with uni-lateral osteoarthritis of the knee or subjects with bi-lateral osteoarthritis of the knee, who have a well functioning and pain free knee replacement in the contralateral knee.\n* Subjects who require a TKR for surgical management of osteoarthritis\n\nExclusion Criteria:\n\n* Patients who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in the study.\n* Patients with bi-lateral disease that significantly impacts on their current function and pain.\n* Patients who require revision knee arthroplasty surgery.\n* Disorders of the feet, ankles, hips or spine causing significant abnormal gait or significant pain.\n* Neurological conditions affecting movement.\n* Patients with a pathology, which, in the opinion of the Chief Investigator, will adversely affect healing.\n* Patients with other disorders which, in the opinion of the Chief Investigator, will\u002Fcould impair rehabilitation.\n* Subjects who in the opinion of the study investigator are unlikely to comply with the study follow-up protocol",{"count":126,"type":22},144,[128],"NA","To compare the differences, if any, in clinical outcome, patient satisfaction and survivorship between cemented and uncemented Total Knee Replacements (TKR)? To investigate if there are health economic implications of using uncemented TKRs in the NHS?",[131,33],"Total Knee Replacement",[133,33,134,135,136],"Total Knee Replacements","Orthopedic devices","Arthroplasty","Uncemented","2025-06-20",{"date":139,"type":43},"2025-06-25",{"date":141,"type":43},"2022-05-10",{"date":143,"type":22},"2035-06-30",{"name":145,"class":50},"NHS Greater Glasgow and Clyde",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":51},"100491286","phase-2-influence-of-an-anti-osteoporotic-drug-on-healing-after-surgical-repair-of-chronic-rotator-cuff-lesions-of-the-shoulder-100491286","NCT05677152","Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder","Influence of Zoledronic Acid on Healing After Arthroscopic Repair of Chronic Rotator Cuff Lesions - A Prospective, Randomized, Placebo-controlled Phase II Trial","ZORRO","Inclusion Criteria\n\n* Age between 50 and 70 years\n* Magnetic resonance imaging verified rotator cuff tear (within 6 month prior to surgery)\n* Rupture size with a maximum diameter of 3 cm\n* Willingness to participate in the study\n* Willingness to participate in a unified physiotherapy with use of a shoulder abduction pad for four weeks postoperativel\n\nExclusion Criteria:\n\n* Patients younger than 50 or older than 70 years of age\n* Pregnancy\n* Known allergy to zoledronic acid or other components of the medicinal product\n* Previous fracture of the affected shoulder\n* Previous surgery of the affected shoulder\n* Previous or existing bacterial infection of the affected shoulder\n* Rupture of more than two tendons in the affected shoulder (massive rotator cuff tear)\n* Isolated subscapularis tendon tear\n* Presence of glenohumeral osteoarthritis (Hamada type 3 or higher)\n* Diabetes mellitus (fasting glucose ≥ 126 mg\u002Fdl, HbA1C ≥ ZORRO Version Draft1.0\u002F09.05.2022 Page 6 of 42 6.5%)\n* Malignant tumor disease\n* Pathological dental status\n* Known disease that interferes with bone metabolism\n* Concomitant diseases that do not permit general anesthesia\n* Previous therapy with anti-osteoporotic drugs (bisphosphonates, denosumab, teriparatide)\n* Epilepsy\n* Claustrophobia\n* Chronic alcohol abuse\n* Drug abuse","50 Years","70 Years",{"count":157,"type":22},80,[159],"PHASE2","This is a prospective, single-center, placebo-controlled, non-comparative, phase II study to evaluate the influence of an adjuvant, intravenous therapy with zoledronic acid (single dose) on healing after arthroscopic repair of chronic rotator cuff tears.\n\nThe study including its financial support was approved by the medical director of the General Accident Insurance Institution (AUVA) , Dr. Roland Frank.\n\nHypothesis to prove: Adjuvant intravenous therapy with zoledronic acid does improve tendon healing after arthroscopic reconstruction of chronic rotator cuff tears compared to a control group without adjuvant therapy with zoledronic acid.,",[33,162],"Traumatology",[164,165,166],"zoledronic acid","chronic rotator cuff tears","arthroscopic repair","2024-03-14",{"date":169,"type":43},"2024-03-18",{"date":171,"type":43},"2022-08-22",{"date":173,"type":22},"2030-12",{"name":175,"class":50},"AUVA Traumazentrum Vienna Site UKH Meidling"]